Vincent Fabian Thomas (The Jakarta Post)
Wed, June 30, 2021
As Indonesia continues to see record numbers of new COVID-19 infections in recent days, some local pharmaceuticals are enjoying a windfall this year, but not all companies have been able to cash in on the “pandemic boom”.
PT Kalbe Farma, which claims to be the largest publicly listed pharmaceutical company in Southeast Asia, has seen vitamin and supplement sales grow between 10 and 20 percent annually as consumers seek ways to boost their immune system.
While these products contribute only 3 to 5 percent to overall sales, the company has seen drug sales grow 4 to 5 percent to date to contribute 15 to 20 percent to overall sales. This, Kalbe said, was primarily because consumers had become more confident lately about visiting hospitals for treatment unrelated to the coronavirus.
In addition, Kalbe Farma has expanded its business to COVID-1…
to Read Full Story
Starting from IDR 55,000/month
- Unlimited access to our web and app content
- e-Post daily digital newspaper
- No advertisements, no interruptions
- Privileged access to our events and programs
- Subscription to our newsletters